Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioScience Health Innovations (BHIC) Receivables (2023 - 2026)

BioScience Health Innovations has reported Receivables over the past 4 years, most recently at $78278.0 for Q1 2026.

  • Quarterly Receivables fell 16.23% to $78278.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $78278.0 through Mar 2026, down 16.23% year-over-year, with the annual reading at $536975.0 for FY2025, 339.84% up from the prior year.
  • Receivables was $78278.0 for Q1 2026 at BioScience Health Innovations, down from $536975.0 in the prior quarter.
  • Over five years, Receivables peaked at $536975.0 in Q4 2025 and troughed at $3849.0 in Q1 2023.
  • The 4-year median for Receivables is $36448.0 (2023), against an average of $110755.2.
  • Year-over-year, Receivables surged 1311.56% in 2025 and then dropped 16.23% in 2026.
  • A 4-year view of Receivables shows it stood at $36448.0 in 2023, then skyrocketed by 234.95% to $122083.0 in 2024, then soared by 339.84% to $536975.0 in 2025, then tumbled by 85.42% to $78278.0 in 2026.
  • Per Business Quant, the three most recent readings for BHIC's Receivables are $78278.0 (Q1 2026), $536975.0 (Q4 2025), and $63212.0 (Q3 2025).